| ［1］ |
Cathcart-Rake EJ，Ruddy KJ，Bleyer A，et al. Breast cancer in adolescent and young adult women under the age of 40 years［J］.JCO Oncol Pract，2021，17（6）： 305-313.
|
| ［2］ |
Di Lascio S，Tognazzo E，Bigiotti S，et al. Breast cancer in the oldest old （≥89 years）： tumor characteristics，treatment choices，clinical outcomes and literature review［J］.Eur J Surg Oncol，2021，47（4）： 796-803.
|
| ［3］ |
Xie Y，Deng Y，Wei S，et al. Age has a U-shaped relationship with breast cancer outcomes in women： a cohort study［J］.Front Oncol，2023，13： 1265304.
|
| ［4］ |
Cai S，Zuo W，Lu X，et al. The prognostic impact of age at diagnosis upon breast cancer of different immunohistochemical subtypes： a surveillance，epidemiology，and end results （SEER） population-based analysis［J］.Front Oncol，2020，10： 1729.
|
| ［5］ |
Van den Brandt PA，Ziegler RG，Wang M，et al. Body size and weight change over adulthood and risk of breast cancer by menopausal and hormone receptor status： a pooled analysis of 20 prospective cohort studies［J］.Eur J Epidemiol，2021，36（1）： 37-55.
|
| ［6］ |
Ruhstaller T，Giobbie-Hurder A，Colleoni M，et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer： long-term follow-up of the BIG 1-98 trial［J］.J Clin Oncol，2019，37（2）： 105-114.
|
| ［7］ |
Kim SW，Chun M，Jung YS，et al. Impact of body mass index on local recurrence according to intrinsic subtype approximation in Korean women with early stage invasive breast cancer receiving contemporary treatments［J］.J Cancer，2021，12（15）： 4648-4654.
|
| ［8］ |
Chen B，Lai J，Guo L，et al. Adverse effects of being underweight on young female breast cancer patients with lymph node metastases［J］.J Cancer，2020，11（7）： 1976-1984.
|
| ［9］ |
Liu Y，He M，Zuo WJ，et al. Tumor size still impacts prognosis in breast cancer with extensive nodal involvement［J］.Front Oncol，2021，11： 585613.
|
| ［10］ |
Chu J，Yang D，Wang L，et al. Nomograms predicting survival for all four subtypes of breast cancer： a SEER-based population study［J］.Ann Transl Med，2020，8（8）： 544.
|
| ［11］ |
Okuno J，Miyake T，Sota Y，et al. Development of prediction model including microRNA expression for sentinel lymph node metastasis in ER-positive and HER2-negative breast cancer［J］.Ann Surg Oncol，2021，28（1）： 310-319.
|
| ［12］ |
Herr D，Wischnewsky M，Joukhadar R，et al. Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer？ A retrospective multicenter study［J］.PLoS One，2019，14（7）： e0218434.
|
| ［13］ |
Soran A，Ozmen T，Salamat A，et al. Lymph node ratio （LNR）： predicting prognosis after neoadjuvant chemotherapy （NAC） in breast cancer patients［J］.Eur J Breast Health，2019，15（4）： 249-255.
|
| ［14］ |
Li Y，Ma L. Nomograms predict survival of patients with lymph node-positive，luminal A breast cancer［J］.BMC Cancer，2021，21（1）： 965.
|
| ［15］ |
Fu WD，Wang XH，Lu KK，et al. Real-world outcomes for Chinese breast cancer patients with tumor location of central and nipple portion［J］.Front Surg，2022，9： 993263.
|
| ［16］ |
Wei Y，Liu P，Liu X，et al. Analysis of the relationship between primary tumor site and clinicopathological characteristics and survival prognosis of breast cancer patients based on SEER database［J］.Clin Breast Cancer，2024，24（8）：728-745.
|
| ［17］ |
Ansari B，Morton MJ，Adamczyk DL，et al. Distance of breast cancer from the skin and nipple impacts axillary nodal metastases［J］.Ann Surg Oncol，2011，18（11）： 3174-3180.
|
| ［18］ |
Erber R，Hartmann A. Histology of luminal breast cancer［J］.Breast Care （Basel），2020，15（4）： 327-336.
|
| ［19］ |
Gradishar WJ，Moran MS，Abraham J，et al. Breast cancer，version 3.2022，NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw，2022，20（6）： 691-722.
|
| ［20］ |
Kim J，Kim JY，Lee HB，et al. Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification： comparative analysis to invasive carcinoma of no special type［J］.Breast Cancer Res Treat，2020，184（2）： 527-542.
|
| ［21］ |
Jin X，Zhou YF，Ma D，et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer［J］.Nat Genet，2023，55（10）： 1696-1708.
|
| ［22］ |
Song SE，Cho KR，Cho Y，et al. Machine learning with multiparametric breast MRI for prediction of Ki-67 and histologic grade in early-stage luminal breast cancer［J］.Eur Radiol，2022，32（2）： 853-863.
|
| ［23］ |
Liang Q，Ma D，Gao RF，et al. Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes［J］.Sci Rep，2020，10（1）：7648.
|
| ［24］ |
Ehinger A，Malmstrom P，Bendahl PO，et al. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013［J］.Acta Oncol，2017，56（1）： 68-74.
|
| ［25］ |
Isheden G，Grassmann F，Czene K，et al. Lymph node metastases in breast cancer： investigating associations with tumor characteristics，molecular subtypes and polygenic risk score using a continuous growth model［J］.Int J Cancer，2021，149（6）： 1348-1357.
|
| ［26］ |
Xiao W，Zheng S，Yang A，et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis： a population-based study［J］.Cancer Manag Res，2018，10： 5329-5338.
|
| ［27］ |
Xu Z，Chen Y，Dai Y，et al. Prognostic factors for hormone receptor-positive breast cancer with liver metastasis and establishment of novel nomograms for prediction： a SEER-based study［J］.Transl Cancer Res，2023，12（12）： 3672-3692.
|
| ［28］ |
Pu CC，Yin L，Yan JM. Risk factors and survival prediction of young breast cancer patients with liver metastases： a population-based study［J］.Front Endocrinol （Lausanne），2023，14：1158759.
|
| ［29］ |
Riecke K，Muller V，Neunhoffer T，et al. Long-term survival of breast cancer patients with brain metastases： subanalysis of the BMBC registry［J］.ESMO Open，2023，8（3）：101213.
|
| ［30］ |
Sabatier R，Martin J，Vicier C，et al. Eribulin efficacy on brain metastases in heavily pretreated patients with metastatic breast cancer［J］.J Clin Med，2021，10（6）： 1272.
|
| ［31］ |
You CP，Leung MH，Tsang WC，et al. Androgen receptor as an emerging feasible biomarker for breast cancer［J］.Biomolecules，2022，12（1）： 72.
|
| ［32］ |
Castellano I，Allia E，Accortanzo V，et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers［J］.Breast Cancer Res Treat，2010，124（3）： 607-617.
|
| ［33］ |
Okano M，Oshi M，Butash AL，et al. Estrogen receptor positive breast cancer with high expression of androgen receptor has less cytolytic activity and worse response to neoadjuvant chemotherapy but better survival［J］.Int J Mol Sci，2019，20（11）： 2655.
|
| ［34］ |
Zhong W，Yi J，Wu H，et al. Androgen receptor expression and its prognostic value in T1N0 luminal/HER2-negative breast cancer［J］.Future Oncol，2022，18（14）： 1745-1756.
|
| ［35］ |
Shandiz FH，Shabahang H，Afzaljavan F，et al. Ki67 frequency in breast cancers without axillary lymph node involvement and its relation with disease-free survival［J］.Asian Pac J Cancer Prev，2016，17（3）： 1347-1350.
|
| ［36］ |
Yamanouchi K，Kuba S，Eguchi S. Hormone receptor，human epidermal growth factor receptor-2，and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases［J］.Surg Today，2020，50（7）： 657-663.
|
| ［37］ |
Coates AS，Winer EP，Goldhirsch A，et al. Tailoring therapies--improving the management of early breast cancer： St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015［J］.Ann Oncol，2015，26（8）： 1533-1546.
|
| ［38］ |
Goldhirsch A，Wood WC，Coates AS，et al. Strategies for subtypes--dealing with the diversity of breast cancer： highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011［J］.Ann Oncol，2011，22（8）： 1736-1747.
|
| ［39］ |
Goldhirsch A，Winer EP，Coates AS，et al. Personalizing the treatment of women with early breast cancer： highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013［J］.Ann Oncol，2013，24（9）： 2206-2223.
|
| ［40］ |
Lombardi A，Lazzeroni R，Bersigotti L，et al. The proper Ki-67 cut-off in hormone responsive breast cancer： a monoinstitutional analysis with long-term follow-up［J］.Breast Cancer （Dove Med Press），2021，13： 213-217.
|
| ［41］ |
Grote I，Bartels S，Kandt L，et al. TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer［J］.Cancer Med，2021，10（23）： 8581-8594.
|
| ［42］ |
Lee SK，Bae SY，Lee JH，et al. Distinguishing low-risk luminal A breast cancer subtypes with Ki-67 and p53 is more predictive of long-term survival［J］.PLoS One，2015，10（8）： e0124658.
|
| ［43］ |
周俊臻，许馨文，唐晶晶，等. 突变型p53作为乳腺癌的潜在治疗靶点的研究进展［J］.临床医学进展，2021，11（11）： 5455-5460.
|
| ［44］ |
Albinsaad LS，Kim J，Chung IY，et al. Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy［J］.Breast Cancer Res Treat，2021，187（2）： 447-454.
|
| ［45］ |
Zhao W，Li X，Wang W，et al. Association of preoperative serum levels of CEA and CA15-3 with molecular subtypes of breast cancer［J］.Dis Markers，2021，2021： 5529106.
|
| ［46］ |
Khushk M，Khan A，Rehman A，et al. The role of tumor markers： carcinoembryonic antigen and cancer antigen 15-3 in patients with breast cancer［J］.Cureus，2021，13（7）： e16298.
|
| ［47］ |
Li J，Liu L，Feng Z，et al. Tumor markers CA15-3，CA125，CEA and breast cancer survival by molecular subtype： a cohort study［J］.Breast Cancer，2020，27（4）： 621-630.
|
| ［48］ |
Shao Y，Sun X，He Y，et al. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer［J］.PLoS One，2015，10： e0133830.
|
| ［49］ |
Imamura M，Morimoto T，Nomura T，et al. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes［J］.World J Surg Oncol，2018，16（1）： 26.
|
| ［50］ |
Zuo D，Yang L，Jin Y，et al. Machine learning-based models for the prediction of breast cancer recurrence risk［J］.BMC Med Inform Decis Mak，2023，23（1）： 276.
|
| ［51］ |
谭璐媛，王妍，钟文静，等. 乳腺肿瘤免疫微环境及其在临床免疫治疗中的应用［J/CD］.中华乳腺病杂志（电子版），2018，12（3）： 165-171.
|
| ［52］ |
Ni Y，Tsang JY，Shao Y，et al. Combining analysis of tumor-infiltrating lymphocytes （TIL） and PD-L1 refined the prognostication of breast cancer subtypes［J］.Oncologist，2022，27（4）： e313-e327.
|
| ［53］ |
Liu J，Wang X，Deng Y，et al. Research progress on the role of regulatory T cell in tumor microenvironment in the treatment of breast cancer［J］.Front Oncol，2021，11： 766248.
|
| ［54］ |
Kyte JA，Andresen NK，Russnes HG，et al. ICON： a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer［J］.J Transl Med，2020，18（1）： 269.
|
| ［55］ |
Lukianova Y，Mushii O，Krotevych M，et al. PD-L1 expression in receptor-negative breast cancer tissue［J］.Exp Oncol，2025，46（4）： 324-332.
|
| ［56］ |
Al-Sharabass EA，El-Houseini ME，Effat H，et al. The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer［J］.Mol Med，2025，31（1）： 106.
|
| ［57］ |
王晓露，孟凡岩，李茹恬，等. 乳腺癌组织肿瘤细胞和间质免疫细胞程序性死亡配体-1表达与临床病理特征的关系［J］.中华实用诊断与治疗杂志，2022，36（9）： 912-915.
|
| ［58］ |
Suppan C. ESMO 2021-my top three abstracts in breast cancer［J］. Memo，2022，15（2）： 111-113.
|
| ［59］ |
Debien V，De Caluwe A，Wang X，et al. Immunotherapy in breast cancer： an overview of current strategies and perspectives［J］.NPJ Breast Cancer，2023，9（1）： 7.
|
| ［60］ |
Okano M，Oshi M，Butash AL，et al. Estrogen receptor positive breast cancer with high expression of androgen receptor has less cytolytic activity and worse response to neoadjuvant chemotherapy but better survival［J］.Int J Mol Sci，2019，20（11）： 2655.
|
| ［61］ |
Paoletti C，Regan MM，Niman SM，et al. Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients［J］.NPJ Breast Cancer，2021，7（1）： 77.
|
| ［62］ |
Pascual J，Attard G，Bidard FC，et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer： a report from the ESMO Precision Medicine Working Group［J］.Ann Oncol，2022，33（8）： 750-768.
|
| ［63］ |
Guan X，Li C，Li Y，et al. Epithelial-mesenchymal-transition-like circulating tumor cell-associated white blood cell clusters as a prognostic biomarker in HR-positive/HER2-negative metastatic breast cancer［J］.Front Oncol，2021，11： 602222.
|
| ［64］ |
Magbanua MJM，Swigart LB，Wu HT，et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival［J］.Ann Oncol，2021，32（2）： 229-239.
|
| ［65］ |
Bharde A，Nadagouda S，Dongare M，et al. ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients［J］.J Liq Biopsy，2024，7： 100284.
|